Cytokinetics (CYTK) Misses Q1 EPS by 7c
Tweet
Share
E-mailGet Alerts CYTK Hot Sheet
Price: $72.72 --0%
Revenue Growth %: +1,960.6%
Financial Fact:
Net loss: 31.89M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +1,960.6%
Financial Fact:
Net loss: 31.89M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Cytokinetics (NASDAQ: CYTK) reported Q1 EPS of ($0.54), $0.07 worse than the analyst estimate of ($0.47). Revenue for the quarter came in at $8.5 million versus the consensus estimate of $6.86 million.
For earnings history and earnings-related data on Cytokinetics (CYTK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- HSBC Raises S&P500 Target to 8,100
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Hyperion DeFi raises FY26 guidance, launches $20M buyback
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
